Atossa Genetics (NASDAQ:ATOS) was upgraded by ValuEngine from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Friday.
Separately, Maxim Group reaffirmed a “buy” rating and set a $5.00 target price on shares of Atossa Genetics in a research note on Wednesday, January 9th.
Shares of ATOS stock opened at $7.07 on Friday. Atossa Genetics has a 12 month low of $0.80 and a 12 month high of $7.56.
An institutional investor recently bought a new position in Atossa Genetics stock. Barclays PLC bought a new position in shares of Atossa Genetics Inc (NASDAQ:ATOS) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 32,384 shares of the company’s stock, valued at approximately $33,000. Barclays PLC owned 0.57% of Atossa Genetics at the end of the most recent reporting period. 13.87% of the stock is currently owned by institutional investors.
Atossa Genetics Company Profile
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.